NCT05541224 is a clinical trial in Acute Myeloid Leukemia, sponsored by PETHEMA Foundation.

Who is sponsoring NCT05541224?

NCT05541224 is sponsored by PETHEMA Foundation.

What condition does NCT05541224 study?

NCT05541224 studies Acute Myeloid Leukemia.

Is NCT05541224 still recruiting?

NCT05541224 is currently completed. Last updated 15 September 2022.

Last reviewed 2022-09-15 · How we verify

NCT05541224

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

Completed Last updated 15 September 2022

What this trial tests

trial in Acute Myeloid Leukemia in 6,917 participants. Completed in 1 October 2020.

Timeline

1 November 2019

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	PETHEMA Foundation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6,917
Start date	1 November 2019
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	22 locations across Spain

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

PETHEMA Foundation

Who can join

18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective, translational, epidemiologic, multicenter, non-interventional study (No EPA study) to provide insights into disease epidemiology, disease biology, treatment regimens, and clinical outcomes of patients with acute myeloblastic leukemia (AML) in routine clinical practice according to their molecular markers. The primary objective of the study is to describe the use of the main molecular markers (FLT3 and NPM1) in the real-life according of the type of AML, treating institution, patients' characteristics, and disease status.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador J, Martínez-Cuadrón D, Boluda B, Serrano J, et al · · 2024 · cited 3× · PMID 38896056 · DOI 10.1002/cncr.35431

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other PETHEMA Foundation trials

Trials by the same sponsor.

NCT07443592 — Treatment for Ph-negative ALL for Adults up to 65 Years · NA · not yet recruiting
NCT07045909 — Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · Phase 2 · recruiting
NCT06574126 — Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma · Phase 2 · recruiting
NCT06544785 — Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Phase 2 · recruiting
NCT06175702 — Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05541224 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PETHEMA Foundation
Last refreshed: 15 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05541224.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing